A drug Sanofi inherited in its acquisition of Genzyme more than a decade ago has just become the first approved treatment for the neurological symptoms of a rare lysosomal storage disorder.
The French pharmaceutical company said Wednesday that its once-daily pill, to be sold as Infilbray, was cleared in the U.S. for adults or children weighing at least 15 kilograms and who have the “Type 3” form of Gaucher disease. It’s one of many products Sanofi hopes can boost sales ahead of the looming patent expiration of the company’s top-selling drug, Dupixent.
“Patients living with Type 3 Gaucher disease face a long and difficult road to accurate diagnosis, often going years without answers while neurological manifestations progress,” said Aviva Rosenberg the CEO and co-founder of the nonprofit Gaucher Community Alliance, in a statement provided by Sanofi. “Today’s Infilbray approval marks a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease.”
Sanofi picked up Infilbray when it purchased rare disease drug giant Genzyme in 2011. In the years since, Sanofi has evaluated it against a variety of disorders.
Infilbray’s development has been riddled with setbacks, however. It failed clinical testing in Parkinson’s disease, a rare kidney condition, the lysosomal storage disorder known as GM2 gangliosidosis and more recently Fabry disease.
Yet the drug finally came through against Gaucher disease, an inherited disorder in which the deficiency of a key enzyme leads to a toxic buildup of fat-like molecules called glycosphingolipids. In the Type 3 form of Gaucher, those molecules gather in the central nervous system and affect cognitive function and coordination.
Infilbray is designed to stop that accumulation and slow disease progression. In the Phase 3 trial underlying its approval, a year of treatment was associated with statistically significant improvements in neurological symptoms. The drug’s prescribing information carries warnings for suicidal thoughts and behaviors, clouding of the eye’s lens in pediatric patients and possible damage to a developing fetus.
The approval gives Sanofi another source of revenue as a new CEO navigates the company through a sizable patent cliff. In a September note to clients, however, RBC Markets analyst Trung Huynh wrote that sales expectations are modest and Sanofi “will need more than a few successful rare disease drugs to help curb” the coming loss of Dupixent revenue.
Sanofi hasn’t disclosed Infilbray’s price. In an email to BioPharma Dive, a company spokesperson said the price “will incorporate the clinical value compared to existing treatments, economic impact on overall healthcare costs, social contributions to quality of life, and system-wide affordability.”